BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 3727710)

  • 1. Anticoagulation is necessary in patients with atrial fibrillation after mitral valve replacement with bioprostheses.
    Rothlin ME
    Z Kardiol; 1986; 75 Suppl 2():317-20. PubMed ID: 3727710
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral anticoagulation is not necessary for patients with bioprosthetic mitral valve replacement in atrial fibrillation.
    Nuñez L; Pinto AG; Larrea JL; Gil Aguado M; Connor FO
    Z Kardiol; 1986; 75 Suppl 2():321-5. PubMed ID: 3727711
    [No Abstract]   [Full Text] [Related]  

  • 3. Low profile bioprostheses for mitral valve replacement.
    Romano M; Sigal R; Lorente P; Piwnica A
    Z Kardiol; 1986; 75 Suppl 2():305-7. PubMed ID: 3727708
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors influencing thromboembolism after mitral prosthetic implants.
    Rábago G; Fraile J; Martinell J; Artiz V; Cortina J
    Z Kardiol; 1986; 75 Suppl 2():341-4. PubMed ID: 2425504
    [No Abstract]   [Full Text] [Related]  

  • 5. High complication and failure rates of anticoagulant therapy are unavoidable.
    Nitter-Hauge S; Dale J
    Z Kardiol; 1986; 75 Suppl 2():293-7. PubMed ID: 3727705
    [No Abstract]   [Full Text] [Related]  

  • 6. Can early thromboembolic complications after valve replacement be avoided?
    Kure HH; Schüller H; Thulin L; Olin C
    Z Kardiol; 1986; 75 Suppl 2():302-4. PubMed ID: 3727707
    [No Abstract]   [Full Text] [Related]  

  • 7. Left atrial appendage exclusion and the risk of thromboembolic events following mitral valve surgery.
    Almahameed ST; Khan M; Zuzek RW; Juratli N; Belden WA; Asher CR; Novaro GM; Martin DO; Natale A
    J Cardiovasc Electrophysiol; 2007 Apr; 18(4):364-6. PubMed ID: 17286567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulation in valvular heart disease preoperatively and postoperatively.
    Bodnar AG; Hutter AM
    Cardiovasc Clin; 1984; 14(3):247-64. PubMed ID: 6722854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation is necessary in all patients with mechanical prostheses in sinus rhythm.
    Duveau D
    Z Kardiol; 1986; 75 Suppl 2():326-31. PubMed ID: 3727712
    [No Abstract]   [Full Text] [Related]  

  • 10. Seventeen-year experience with the St. Jude medical biocor porcine bioprosthesis.
    Mykén PS
    J Heart Valve Dis; 2005 Jul; 14(4):486-92. PubMed ID: 16116875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Replacement of the mitral and aortic valves with bioprostheses. Long-term results].
    Colombo T; Cicardi C; Peronace B; Pozzi M; Gordini V; Pellegrini A
    G Ital Cardiol; 1985 Oct; 15(10):974-82. PubMed ID: 4092917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results after mitral and aortic valve replacement in childhood and adolescence.
    Rupprath G; Franke F; Vogt J; de Vivie ER
    Z Kardiol; 1986; 75 Suppl 2():312-6. PubMed ID: 2425503
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis.
    Aramendi JL; Agredo J; Llorente A; Larrarte C; Pijoan J
    J Heart Valve Dis; 1998 Nov; 7(6):610-4. PubMed ID: 9870193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement.
    Blair KL; Hatton AC; White WD; Smith LR; Lowe JE; Wolfe WG; Young WG; Oldham HN; Douglas JM; Glower DD
    Circulation; 1994 Nov; 90(5 Pt 2):II214-9. PubMed ID: 7955256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial.
    Aramendi JI; Mestres CA; Martinez-León J; Campos V; Muñoz G; Navas C
    Eur J Cardiothorac Surg; 2005 May; 27(5):854-60. PubMed ID: 15848326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carpentier-Edwards supra-annular porcine bioprosthesis--new generation biological valve.
    Jamieson WR; Gerein AN; Tyers GF; Allen P; Munro AI; Miyagishima RT; Janusz MT; Burr LH
    Z Kardiol; 1986; 75 Suppl 2():245-50. PubMed ID: 3727695
    [No Abstract]   [Full Text] [Related]  

  • 17. Eighteen-year follow up after Hancock II bioprosthesis insertion.
    Legarra JJ; Llorens R; Catalan M; Segura I; Trenor AM; de Buruaga JS; Rabago G; Sarralde A
    J Heart Valve Dis; 1999 Jan; 8(1):16-24. PubMed ID: 10096477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do all patients with mechanical heart valve prostheses need anticoagulant therapy?
    Dale J; Nitter-Hauge S
    Z Kardiol; 1986; 75 Suppl 2():332-7. PubMed ID: 3727714
    [No Abstract]   [Full Text] [Related]  

  • 19. Aortic and mitral valve replacement in young patients.
    Vouhé PR; Milano A; Leca F; Neveux JY
    Z Kardiol; 1986; 75 Suppl 2():289-92. PubMed ID: 3727704
    [No Abstract]   [Full Text] [Related]  

  • 20. [A study on prosthetic valves with reference to anticoagulation-related complications].
    Sakashita I; Otani S; Hayashi J; Eguchi S
    Rinsho Kyobu Geka; 1981; 1(1):43-55. PubMed ID: 7052581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.